openPR Logo
Press release

Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market

05-26-2017 07:45 AM CET | Health & Medicine

Press release from: Transparency Market Research

Chronic Inflammatory Demyelinating Polyneuropathy (CIPD)

Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses.

Myelin acts as an insulation and allows efficient flow of electrical impulses through the nerve fibers. In patients suffering from CIPD the immune system damages or destroys the myelin due to which the nerve fibers become weak, this leads to loss or weakening of the electrical impulses in the arms and legs and cause weakness or loss of sensation.

Obtain Report Details @ http://www.transparencymarketresearch.com/chronic-inflammatory-demyelinating-polyneuropathy-treatment-market.html

CIPD can occur at any age and in both genders. However the frequency of incidence is high among men as compared to women. The rate of recovery of the patient depends on the early diagnosis of the disease. Most CIPD patients respond well to the therapy if it is provided at the early stage of onset of the disorder so that the damage to the peripheral nerves can be controlled which contributes to the improved function and better quality of life for the patient.

With increasing number of new cases of CIDP and absence of permanent treatment is increasing the prevalence rate of CIPD globally. According to the American Association of Neuromuscular & Electrodiagnostic Medicine approximately 40,000 patients in the U.S. are affected by CIPD at any one time in time. The growing prevalence rate is expected to boost demand for CIPD treatment over the forecast period. Growing research in the field of CIPD treatment is expected to deliver new drugs which in turn is expected to increase the demand for CIPD treatment drugs over the forecast period. As per the clinicaltrials. gov currently there are 38 ongoing clinical trials for CIPD treatment.

Organizations like GBS/CIPD Foundation International are focusing on creating awareness about CIPD and similar disorders by providing support to the patients and their families and caregivers and are focusing on development of national and international support groups. Awareness and support initiatives are expected to propel revenue growth. However the awareness initiatives are gaining traction in developed economies the awareness of CIPD and related treatments remain low in emerging low income economies.

Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16256

The CIPD treatment market is segmented by treatment type and by geography. By treatment type the global CIPD treatment market is segmented into corticosteroids, intravenous immunoglobulin and plasmapheresis (plasma exchange). Along with the primary treatment methods physicians also opt for of the treatments like chemotherapy, physiotherapy for strengthening the muscles. The secondary treatments are mainly preferred when primary treatments fail or exhibit side effects on the patient’s health.

By geography the global CIPD treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific (APAC) and Middle East and Africa (MEA). North America and Europe are expected to dominate the CIPD treatment market over the forecast period. Increasing research and awareness programs are expected to promote revenue growth of CIPD treatment market in these regions. Asia Pacific CIPD treatment market is expected to witness high growth owing to high population which in turn is expected to increase the prevalence rate of CIPD in this region. Latin America and MEA are expected to follow up with the other regions owing to growing awareness, growing healthcare infrastructure and increasing per capita healthcare spending.

Some key participants in the CIPD treatment market are Baxter International Inc., Kedrion S.p.A, Octapharma AG, CSL Behring, Grifols, S.A. and others.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market here

News-ID: 551326 • Views: 325

More Releases from Transparency Market Research

Dielectric Gases Market Shares, Strategies and Opportunities 2027
Overview TMR’s report on the Dielectric Gases Market is an all-important tool for market stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Dielectric Gases market serves as a valuable guide for market stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Dielectric Gases market over the
Oxalic Acid Market Size will Observe Lucrative Surge by the End 2027
Overview TMR’s report on the Oxalic Acid Market is an all-important tool for market stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Oxalic Acid market serves as a valuable guide for market stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Oxalic Acid market over the
Long Fiber Thermoplastics Market Shares, Strategies and Opportunities 2027
Overview TMR’s report on the Long Fiber Thermoplastics Market is an all-important tool for market stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Long Fiber Thermoplastics market serves as a valuable guide for market stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Long Fiber Thermoplastics
High Performance Foaming Agents Market Size will Observe Lucrative Surge by the …
Overview TMR’s report on the High Performance Foaming Agents Market is an all-important tool for market stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the High Performance Foaming Agents market serves as a valuable guide for market stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the High

All 5 Releases


More Releases for CIPD

The CIPD accredits a further two Engage in Learning e-learning courses
The only body in the world that’s able to award Chartered status to individual HR and L&D professionals - the CIPD - has accredited a further two e-learning courses from Engage in Learning. Hot on the heels of the CIPD accrediting Engage in Learning’s ‘Unconscious Bias’ and ‘Unconscious Bias for Managers’ courses, confirming that their learning value and structure conforms to continuous professional development (CPD) guidelines, comes news that the CIPD
CIPD accredits Unconscious Bias e-learning courses from Engage in Learning
Two e-learning courses from Engage in Learning covering unconscious bias have been accredited by the CIPD - the only body in the world that can award Chartered status to individual HR and L&D professionals. In officially accrediting the Engage in Learning courses – ‘Unconscious Bias’ and ‘Unconscious Bias for Managers’ – the CIPD confirmed that their learning value and structure conforms to CPD guidelines. Moreover, the courses’ assessor, from the CIPD,
Learns Details of the Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) T …
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow
Growing Research in the Field of CIPD Treatment is Expected to Deliver New Drugs …
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow
Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market: Curre …
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow
Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market Resear …
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow